Factor VIII/von Willebrand factor - Grifols

Drug Profile

Factor VIII/von Willebrand factor - Grifols

Alternative Names: Alphanate; Fanhdi; Von Willebrand factor/Factor VIII

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Talecris Biotherapeutics
  • Developer Grifols
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A; Von Willebrand disease

Most Recent Events

  • 29 Jul 2016 Grifols initiates a phase II trial for Haemophilia A (In neonates, In infants, In children) in Spain (IV) (EudraCT2015-005524-26)
  • 29 Apr 2016 Biomarkers information updated
  • 23 Nov 2013 Grifols initiates enrolment in a phase IV postmarketing study for Von Willebrand's Disease (in paediatric patients with type I, II or III disease) in Spain (EudraCT2012-003450-92)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top